Citations 1
Results of a multicenter phase I/II trial of abiraterone acetate plus BEZ235 in metastatic, castration-resistant prostate cancer (mCRPC).
Siegel, Adam, Lin, Amy , Friedlander, Terence W. , Hsieh, Andrew C. , Hang, Evelyn, Weinberg, Vivian, Ryan, Charles J. , Bryce, Alan H.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e16042-e16042
